|
Dynavax is notifying all customers and business associates about this change, and we would appreciate your partnership in helping us ensure that all systems and locations involved with HEPLISAV-B are updated with the new HEPLISAV-B pricing.
INDICATION
HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
IMPORTANT SAFETY INFORMATION
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.
Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.
The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).
Please see full Prescribing Information.
For any questions, contact DYNAVAX at 1-84-HEPLISAV (1-844-375-4728)
DYNAVAX and HEPLISAV-B are registered trademarks of Dynavax Technologies Corporation.
© 2024 Dynavax Technologies Corporation. All rights reserved.
US-24-00-00013│February 2024
Dynavax | 2100 Powell Street Suite 900 | Emeryville, CA 94608
www.dynavax.com www.heplisavb.com
| 
